An estimated 40 million people take a statin to lower their cholesterol levels. These are one of the most widely prescribed medications in history and, of course, one of the most profitable.
New research published in the journal PLoS indicates that the use of the cholesterol-lowing class of drugs known as statins is associated with an increased prevalence of microalbuminuria, a well-known marker of vascular dysfunction, affecting both cardiovascular and kidney disease risk.
A recent study, published in the Archives of Internal Medicine, found that the cholesterol-lowering drugs known as statins increase the risk of diabetes within postmenopausal women by 48%.
This new finding adds to a growing body of clinical evidence that statin drugs are fundamentally diabetogenic, which is not surprising considering the National Library of Medicine contains peer-reviewed, published research on over 300 other known adverse effects associated with their use.
